Retail Bulls Back Sarepta After Brazil Death Deemed Unrelated
In a recent development, Sarepta Therapeutics, a biotech company, has faced a setback with the death of an 8-year-old boy in Brazil who was receiving its Duchenne gene therapy, Elevidys. However, despite this incident, retail investors have shown remarkable resilience and continue to back the company, citing the lack of linkage between the therapy and the boy’s death.
According to reports, the Brazilian authorities have concluded that the boy’s death was caused by a viral infection, and not by the gene therapy. The news has been met with a surge in message volume on StockTwits, a popular platform for stock market chatter, with a 65% increase in sentiment. This shows that retail investors are sticking with Sarepta, despite the recent setback.
The FDA is also investigating the incident, but so far, no evidence has been found to link the therapy to the boy’s death. The European Medicines Agency (EMA) had earlier rejected Sarepta’s application for its gene therapy, citing concerns over its safety and efficacy. Additionally, the company had paused the shipment of its gene therapy in the US.
Despite these developments, retail investors seem to be unperturbed, with many of them continuing to hold out hope for the company’s prospects. The message volume on StockTwits has been extremely bullish, with many investors sharing their bullish views on the company’s future prospects.
One investor on StockTwits wrote, “I’m not worried about this incident. The company has been transparent, and the authorities have concluded that there’s no link to the therapy. I’m sticking with Sarepta and expecting big things from them in the future.”
Another investor added, “I’ve been following Sarepta for a while now, and I believe in their technology. Yes, there may be setbacks, but the company is committed to making a difference in the lives of patients. I’m confident that they will overcome this hurdle and come out stronger on the other side.”
The enthusiasm of retail investors is not surprising, given the potential of Sarepta’s gene therapy to revolutionize the treatment of Duchenne muscular dystrophy. The disease is a rare genetic disorder that affects approximately 1 in 5,000 boys, causing progressive muscle weakness and wasting.
Sarepta’s gene therapy, Elevidys, has shown promising results in clinical trials, with patients experiencing significant improvements in muscle strength and function. The therapy works by delivering a functional copy of the dystrophin gene to patients, which helps to restore muscle function and slow down the progression of the disease.
The company has also made significant progress in its research and development efforts, with several clinical trials underway to test the safety and efficacy of its gene therapy. The FDA has granted Sarepta fast-track designation for its gene therapy, which is expected to expedite the review process.
In conclusion, despite the recent setback, retail investors seem to be sticking with Sarepta, citing the lack of linkage between the therapy and the boy’s death. The company’s gene therapy has the potential to revolutionize the treatment of Duchenne muscular dystrophy, and many investors believe that it will overcome the current challenges and come out stronger on the other side.
Source:
